Oscar Patterson-Lomba

Boston
Education
Ph.D., applied mathematics, Arizona State University; B.S., physics, Montclair State University
Summary of Experience
Dr. Patterson-Lomba has broad experience using mathematical epidemiology and statistical approaches to address a wide range of health care research challenges. His expertise includes comparative efficacy and safety, indirect mixed-treatment comparisons, dynamic transmission models, predictive analytics, burden of illness, and individualized medicine, as well as designing and implementing analytics platforms to enhance research capabilities. Dr. Patterson-Lomba has applied statistical methodologies to study clinical and economic outcomes in a broad range of disease areas, including infectious diseases, oncology, psychiatry, immunology, and ophthalmology, and has experience using a variety of data sources, including clinical trials, administrative claims, medical charts, surveys, and medical literature. His research has also involved using complex dynamic models of infectious diseases to assess the cost effectiveness of interventions such as treatment, vaccination, and non-pharmacological strategies. His work has been published in peer-reviewed journals and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Patterson-Lomba was a postdoctoral fellow in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health.
Selected Publishing
-
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
-
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
Journal of Comparative Effectiveness Research, 2020
2020Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J
-
Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis
Journal of Comparative Effectiveness Research, 2020
2020Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J
-
Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer
Breast Journal, 2019
2019Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA
-
-
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer
Current Oncology, 2019
2019Levy BP, J E Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M
-
Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer: A Network Meta-analysis
Clinical Therapeutics. Apr 2018;40(4):628-639 e623
2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA
-
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
2018 Oct;35(10):1564-1577
2018Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL
-
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis
Current Medical Research and Opinion. 2018 Sep;34(9):1645-1652
2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA